APHA:CA:TSX-Aphria Inc (CAD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | TSX

Last Closing Price

CAD 17.35

Change

+0.83 (+5.02)%

Market Cap

CAD 5.23B

Volume

2.44M

Average Target Price

CAD 16.27 (-6.23%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands. It serves patients and consumers through distributors and online. The company is headquartered in Leamington, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-21 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BHC:CA Bausch Health Companies Inc

+1.04 (+2.90%)

CAD12.77B N/A 17.58
WEED:CA Canopy Growth Corporation

+1.72 (+5.34%)

CAD12.32B N/A N/A
CRON:CA Cronos Group Inc

+0.40 (+4.12%)

CAD3.76B 46.76 N/A
ACB:CA Aurora Cannabis Inc

+0.59 (+6.13%)

CAD1.90B 1,171.00 N/A
OGI:CA OrganiGram Holdings Inc

+0.24 (+8.16%)

CAD0.88B -99,999.99 N/A
HEXO:CA HEXO Corp

+0.56 (+8.52%)

CAD0.80B N/A N/A
CWEB:CA Charlotte's Web Holdings, Inc

+0.07 (+1.43%)

CAD0.71B 120.37 N/A
GUD:CA Knight Therapeutics Inc

+0.05 (+0.96%)

CAD0.67B 16.27 4.71
HLS:CA HLS Therapeutics Inc

-0.16 (-0.83%)

CAD0.60B N/A 30.75
TH:CA Theratechnologies Inc

-0.02 (-0.44%)

CAD0.43B 954.70 80.88

ETFs Containing APHA:CA

Symbol Name Weight Mer Price(Change) Market Cap
PZC:CA Invesco FTSE RAFI Canadia.. 0.00 % 0.60 %

N/A

CAD7.81M
HMMJ:CA Horizons Marijuana Life S.. 0.00 % 0.75 %

+0.36 (+3.51%)

CAD0.62B
MCSM:CA Manulife Multifactor Cana.. 0.00 % 0.50 %

N/A

CAD0.14B
SEED:CA Evolve Marijuana Fund 0.00 % 0.75 %

N/A

CAD3.63M
ZFC:CA BMO SIA Focused Canadian .. 0.00 % 0.84 %

-0.22 (-0.59%)

CAD0.07B
HMMJ-U:CA Horizons Marijuana Life S.. 0.00 % 0.75 %

+0.12 (+1.47%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 97.16% 89% B+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 97.16% 89% B+ 98% A+
Trailing 12 Months  
Capital Gain 274.73% 96% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 274.73% 96% A 95% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 25.82% 77% C+ 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.82% 77% C+ 91% A-
Risk Return Profile  
Volatility (Standard Deviation) 126.91% 15% F 4% F
Risk Adjusted Return 20.34% 73% C 42% F
Market Capitalization 5.23B 93% A 82% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 57.08 36% F 12% F
Price/Book Ratio 3.72 23% F 27% F
Price / Cash Flow Ratio -39.13 97% A+ 93% A
EV/EBITDA 598.01 7% F 1% F
Management Effectiveness  
Return on Equity -34.14% 61% D- 15% F
Return on Invested Capital -0.06% 80% B- 42% F
Return on Assets -1.31% 79% C+ 29% F
Debt to Equity Ratio 22.09% 48% F 71% C-
Technical Ratios  
Short Ratio 1.80 53% F 40% F
Short Percent N/A N/A N/A N/A N/A
Beta 2.62 11% F 6% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.